Pancreatic cancer protein biomarker could predict outcomes

Around 90% of cases of pancreatic cancer are pancreatic ductal adenocarcinoma, a cancer of the duct that carries digestive enzymes and bile to the gut. In research published in Nature, a team of researchers from the U.K, U.S., and Germany have found that if a gene, USP9X, is faulty and produces low levels of its tumor-suppressing protein, mice with pancreatic ductal adenocarcinoma are less likely to survive surgery, and there is a higher chance of the cancer metastasizing. If this can be reproduced in humans, levels of the protein could be used as a biomarker to predict patients' outcomes. According to the researchers, the gene could be faulty in 15% of pancreatic cancers, and drugs that correct this could show promise in pancreatic cancer treatment. Press release | Abstract

Suggested Articles

AI-based drug molecule designer XtalPi has secured a mammoth funding round totaling $318.8 million, from global banking and tech investors.

LabCorp has licensed a blood test from Genfit designed to identify patients with risky cases of the liver disease NASH.

Philips has launched a compact, single-use device for physically clearing potentially dangerous blood clots lodged in the arms and legs.